Metabolic HealthTriple-Action Drug UBT251 Beats Semaglutide on Weight Loss in Phase 2 Diabetes Trial
An experimental diabetes drug called UBT251 improved blood sugar and reduced weight in a randomized trial involving 211 Chinese adults with type 2 diabetes. Participants received weekly injections of UBT251, semaglutide, or placebo for 24 weeks. UBT251 lowered HbA1c, a measure of average blood sugar, by about 2 percentage points, compared with 1.77 points for semaglutide and 0.66 points for placebo. Weight loss was significantly greater with UBT251 than with either comparison treatment, although the abstract did not report the amounts lost. Digestive problems were the most common side effects. These findings support larger trials, but do not establish longer life, fewer diabetes complications, or superiority to higher semaglutide doses. This summary is based only on the abstract, which provides limited safety details.
